Profound Medical annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Profound Medical R&D Spending Growth & History (PROF)
Profound Medical's r&d spending was $20.6M for fiscal 2025.
View full Profound Medical company overviewProfound Medical annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $20.6M | $3.6M | +21.40% |
| 2024 | 2024-12-31 | $17.0M | $2.5M | +17.62% |
| 2023 | 2023-12-31 | $14.4M | −$266,000 | −1.81% |
| 2022 | 2022-12-31 | $14.7M | −$587,000 | −3.84% |
| 2021 | 2021-12-31 | $15.3M | $5.4M | +54.13% |
| 2020 | 2020-12-31 | $9.9M | $515,000 | +5.48% |
| 2019 | 2019-12-31 | $9.4M | — | — |
Profound Medical quarterly r&d spending
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $5.7M | −$444,000 | −7.28% |
| Q1 2026 | 2026-03-31 | $5.3M | $454,000 | +9.44% |
| Q4 2025 | 2025-12-31 | $4.3M | −$377,000 | −8.11% |
| Q3 2025 | 2025-09-30 | $5.4M | $1.3M | +30.05% |
| Q2 2025 | 2025-06-30 | $6.1M | $1.9M | +45.02% |
| Q1 2025 | 2025-03-31 | $4.8M | $863,000 | +21.88% |
| Q4 2024 | 2024-12-31 | $4.6M | — | — |
| Q3 2024 | 2024-09-30 | $4.2M | — | — |
| Q2 2024 | 2024-06-30 | $4.2M | — | — |
| Q1 2024 | 2024-03-31 | $3.9M | — | — |
Profound Medical r&d spending trends
Over the last five fiscal years, Profound Medical's r&d spending increased from $9.9M to $20.6M, a change of $10.7M. The latest reported quarter, Q2 2026, shows $5.7M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Profound Medical source filings ↗